Table 4.
Clinical outcomes in participants with a positive test result
| Group 1 |
Group 2 |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total |
Men |
Women |
Total |
Men |
Women |
|||||||
| n | % | n | % | n | % | n | % | n | % | n | % | |
| Participants with positive result | 943 | 532 | 411 | 736 | 401 | 335 | ||||||
| No investigations/incomplete investigations/outcome unknown/excluded | 129 | 13.7 | 73 | 13.7 | 56 | 13.6 | 130 | 17.7 | 65 | 16.2 | 65 | 19.4 |
| Investigations completed | 814 | 86.7 | 459 | 86.6 | 355 | 86.8 | 606 | 82.3 | 336 | 83.8 | 270 | 80.6 |
| Clinical outcomes | n | PPV | n | PPV | n | PPV | n | PPV | n | PPV | n | PPV |
| Cancer | 39 | 4.8 | 23 | 5.0 | 16 | 4.5 | 33 | 5.4 | 19 | 5.7 | 14 | 5.2 |
| High-risk adenoma (HRA) | 190 | 23.3 | 127 | 27.7 | 63 | 17.7 | 115 | 19.0 | 80 | 23.8 | 35 | 13.0 |
| Cancer + HRA | 229 | 28.1 | 150 | 32.7 | 79 | 22.3 | 148 | 24.4 | 99 | 29.5 | 49 | 18.1 |
| All adenoma | 311 | 38.2 | 205 | 44.7 | 106 | 29.9 | 217 | 35.8 | 139 | 41.4 | 78 | 28.9 |
| Total neoplasia (cancer + all adenoma) | 350 | 43.0 | 228 | 49.7 | 122 | 34.4 | 250 | 41.3 | 158 | 47.0 | 92 | 34.1 |
| Hyperplastic polyps | 64 | 7.9 | 40 | 8.7 | 24 | 6.8 | – | – | – | – | – | – |
| Normal/Other pathology (IBD, DD, angiodysplasia, haemorrhoids, etc.,) | 400 | 49.1 | 191 | 41.6 | 209 | 58.9 | – | – | – | – | – | – |
| Group 3 |
Group 4 |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total |
Males |
Females |
Total |
Males |
Females |
|||||||
| n | % | n | % | n | % | n | % | n | % | n | % | |
| Participants with positive result | 732 | 443 | 289 | 626 | 376 | 250 | ||||||
| No investigations/incomplete investigations/outcome unknown/excluded | 80 | 10.9 | 45 | 10.2 | 35 | 12.1 | 84 | 13.4 | 58 | 15.4 | 26 | 10.4 |
| Investigations completed | 652 | 89.8 | 398 | 90.5 | 254 | 88.8 | 542 | 86.6 | 318 | 84.6 | 224 | 89.6 |
| Clinical outcomes | n | PPV | n | PPV | n | PPV | n | PPV | n | PPV | n | PPV |
| Cancer | 50 | 7.7 | 35 | 8.8 | 15 | 5.9 | 38 | 7.0 | 26 | 8.2 | 12 | 5.4 |
| High-risk adenoma (HRA) | 157 | 24.1 | 114 | 28.6 | 43 | 16.9 | 120 | 22.1 | 88 | 27.7 | 32 | 14.3 |
| Cancer + HRA | 207 | 31.7 | 149 | 37.4 | 58 | 22.8 | 158 | 29.2 | 114 | 35.8 | 44 | 19.6 |
| All adenoma | 252 | 38.7 | 181 | 45.5 | 71 | 28.0 | 190 | 35.1 | 130 | 40.9 | 60 | 26.8 |
| Total neoplasia (cancer + all adenoma) | 302 | 46.3 | 216 | 54.3 | 86 | 33.9 | 228 | 42.1 | 156 | 49.1 | 72 | 32.1 |
| Hyperplastic polyps | 58 | 8.9 | 40 | 10.1 | 18 | 7.1 | 32 | 5.9 | 19 | 6.0 | 13 | 5.8 |
| Normal/other pathology (IBD, DD, angiodysplasia, haemorrhoids, etc.) | 292 | 44.8 | 142 | 35.7 | 160 | 63.0 | 284 | 52.4 | 143 | 45.0 | 141 | 62.9 |
IBD, inflammatory bowel disease; DD, diverticular disease; PPV, positive predictive value; –, data were unavailable from Information Services, NHS National Services Scotland